Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Excess mortality in the myelodysplastic syndromes.
Nomdedeu M, Pereira A, Ramos F, Valcárcel D, Costa D, Arnan M, Calvo X, Pomares H, Luño E, Díaz-Campelo M, Collado R, de Paz R, Falantes JF, Pedro C, Marco J, Oirtzabal I, Sánchez-García J, Tormo M, Cedena MT, Nomdedeu B, Sanz G; Spanish MDS Group. Nomdedeu M, et al. Among authors: valcarcel d. Am J Hematol. 2017 Feb;92(2):149-154. doi: 10.1002/ajh.24606. Epub 2016 Dec 7. Am J Hematol. 2017. PMID: 27859564 Free article.
Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.
Finke J, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, Volin L, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Bertz H, Grishina O, Socié G; ATG-Fresenius Trial Group. Finke J, et al. Biol Blood Marrow Transplant. 2012 Nov;18(11):1716-26. doi: 10.1016/j.bbmt.2012.06.001. Epub 2012 Jun 17. Biol Blood Marrow Transplant. 2012. PMID: 22713691 Free article. Clinical Trial.
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socié G; ATG-Fresenius Trial Group. Finke J, et al. Lancet Oncol. 2009 Sep;10(9):855-64. doi: 10.1016/S1470-2045(09)70225-6. Epub 2009 Aug 18. Lancet Oncol. 2009. PMID: 19695955 Clinical Trial.
A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia.
Valcárcel D, Montesinos P, Sánchez-Ortega I, Brunet S, Esteve J, Martínez-Cuadrón D, Ribera JM, Tormo M, Bueno J, Duarte R, Llorente A, Torres JP, Guardia R, Sanz MA, Sierra AJ; CETLAM Group. Valcárcel D, et al. Cancer. 2012 Jan 15;118(2):410-7. doi: 10.1002/cncr.26273. Epub 2011 Jun 29. Cancer. 2012. PMID: 21717435 Free article.
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.
Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, Nomdedeu B, Arenillas L, Luño E, Xicoy B, Amigo ML, Valcarcel D, Nachtkamp K, Ambaglio I, Hildebrandt B, Lorenzo I, Cazzola M, Sanz G. Such E, et al. Among authors: valcarcel d. Blood. 2013 Apr 11;121(15):3005-15. doi: 10.1182/blood-2012-08-452938. Epub 2013 Jan 31. Blood. 2013. PMID: 23372164 Free article.
Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome.
Sánchez-Castro J, Marco-Betés V, Gómez-Arbonés X, Arenillas L, Valcarcel D, Vallespí T, Costa D, Nomdedeu B, Jimenez MJ, Granada I, Grau J, Ardanaz MT, de la Serna J, Carbonell F, Cervera J, Sierra A, Luño E, Cervero CJ, Falantes J, Calasanz MJ, González-Porrás JR, Bailén A, Amigo ML, Sanz G, Solé F. Sánchez-Castro J, et al. Among authors: valcarcel d. Leuk Res. 2013 Jul;37(7):769-76. doi: 10.1016/j.leukres.2013.04.010. Epub 2013 Apr 29. Leuk Res. 2013. PMID: 23639672 Free article.
Impact of graft-versus-host disease prophylaxis on outcomes after myeloablative single-unit umbilical cord blood transplantation.
Sanz J, Picardi A, Hernández Boluda JC, Martín C, Ferrá C, Nozzoli C, Gonzalez-Vicent M, Rambaldi A, Valcarcel D, Verdeguer A, Serrano D, de Heredia CD, Pascual MJ, de Paz R, Montesinos P, Bartolozzi B, Algarotti A, Sanz MA, Arcese W, Sanz GF; GETH and GITMO. Sanz J, et al. Among authors: valcarcel d. Biol Blood Marrow Transplant. 2013 Sep;19(9):1387-92. doi: 10.1016/j.bbmt.2013.07.004. Epub 2013 Jul 11. Biol Blood Marrow Transplant. 2013. PMID: 23850652 Free article.
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
Sánchez-García J, Del Cañizo C, Lorenzo I, Nomdedeu B, Luño E, de Paz R, Xicoy B, Valcárcel D, Brunet S, Marco-Betes V, García-Pintos M, Osorio S, Tormo M, Bailén A, Cerveró C, Ramos F, Diez-Campelo M, Such E, Arrizabalaga B, Azaceta G, Bargay J, Arilla MJ, Falantes J, Serrano-López J, Sanz GF; Spanish Group on Myelodysplastic Syndromes (GES MD). Sánchez-García J, et al. Among authors: valcarcel d. Br J Haematol. 2014 Jul;166(2):189-201. doi: 10.1111/bjh.12876. Epub 2014 Apr 10. Br J Haematol. 2014. PMID: 24716538 Free article.
A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome.
Garcia-Manero G, Gartenberg G, Steensma DP, Schipperus MR, Breems DA, de Paz R, Valcárcel D, Kranenburg B, Reddy M, Komrokji RS. Garcia-Manero G, et al. Among authors: valcarcel d. Am J Hematol. 2014 Sep;89(9):E156-62. doi: 10.1002/ajh.23780. Epub 2014 Jun 23. Am J Hematol. 2014. PMID: 24888488 Free article. Clinical Trial.
167 results